A CAR-T transgenic vector suitable for alleviating cytokine release syndrome by blocking IL6R, comprising: an AmpR sequence comprising ampicillin resistance gene for amplifying target bacterial strains by a large number as shown in SEQ ID NO.1; a prokaryotic replicon pUC Ori sequence for plasmid replication as shown in SEQ ID NO.2; an SV40 Ori sequence of viral replicator for enhancing replication in eukaryotic cells as shown in SEQ ID NO.3; an eWPRE enhanced posttranscriptional regulatory element of Groundhog hepatitis B virus for enhancing the expression efficiency of the transgene as shown in SEQ ID NO.11; a human EFlalpha promoter for eukaryotic transcription of chimeric antigen receptor genes as shown in SEQ ID NO.12; lentivirus packaging cis-elements for lentivirus packaging; a sequence encoding a humanized single-chain antibody fragment specific for human IL6R (IL6RscFv), which is IL6RscFv1 as shown in SEQ ID NO.21, or IL6RscFv2 as shown in SEQ ID NO.22, or IL6RscFv3 as shown in SEQ ID NO.23; an IRES ribosome binding sequence for co-transcription and expression of proteins as shown in SEQ ID NO.25; a sequence encoding an IL6 signal peptide as shown in SEQ ID NO.26; a sequence encoding a human antibody Fc segment as shown in SEQ ID NO.27; and a sequence encoding a second-generation or third-generation chimeric antigen receptor; wherein the expression is started by the human EF1alpha promoter; and wherein (i) the CAR and, (ii) a fusion protein of IL6RscFv and Fc, are co-expressed by IRES ribosome binding sequence, wherein the CAR is expressed on the surface of the cell membrane and, wherein the fusion protein of IL6RscFv and Fc is secreted outside the cell under the guidance of IL6 signal peptide. an AmpR sequence comprising ampicillin resistance gene for amplifying target bacterial strains by a large number as shown in SEQ ID NO.1; a prokaryotic replicon pUC Ori sequence for plasmid replication as shown in SEQ ID NO.2; an SV40 Ori sequence of viral replicator for enhancing replication in eukaryotic cells as shown in SEQ ID NO.3; an eWPRE enhanced posttranscriptional regulatory element of Groundhog hepatitis B virus for enhancing the expression efficiency of the transgene as shown in SEQ ID NO.11; a human EFlalpha promoter for eukaryotic transcription of chimeric antigen receptor genes as shown in SEQ ID NO.12; lentivirus packaging cis-elements for lentivirus packaging; a sequence encoding a humanized single-chain antibody fragment specific for human IL6R (IL6RscFv), which is IL6RscFv1 as shown in SEQ ID NO.21, or IL6RscFv2 as shown in SEQ ID NO.22, or IL6RscFv3 as shown in SEQ ID NO.23; an IRES ribosome binding sequence for co-transcription and expression of proteins as shown in SEQ ID NO.25; a sequence encoding an IL6 signal peptide as shown in SEQ ID NO.26; a sequence encoding a human antibody Fc segment as shown in SEQ ID NO.27; and a sequence encoding a second-generation or third-generation chimeric antigen receptor; wherein the expression is started by the human EF1alpha promoter; and wherein (i) the CAR and, (ii) a fusion protein of IL6RscFv and Fc, are co-expressed by IRES ribosome binding sequence, wherein the CAR is expressed on the surface of the cell membrane and, wherein the fusion protein of IL6RscFv and Fc is secreted outside the cell under the guidance of IL6 signal peptide.